Similar to the aforementioned RELAY trial, a post hoc analysis of the IMpower150 trial indicated that the addition of bevacizumab (a vascular endothelial growth factor A inhibitor) and atezolizumab to carboplatin/paclitaxel chemotherapy improves treatment outcomes in patients with KRASmut NSCLC with concurrent TP53 mutation compared with combining atezolizumab and chemotherapy only.15 This evidence concerns the gene VEGFA and non-small cell lung carcinoma.